慢性淋巴细胞白血病的转移模式

The Cancer Journal Pub Date : 2019-11-01 DOI:10.1097/PPO.0000000000000417

N. Jain, S. O'brien

{"title":"慢性淋巴细胞白血病的转移模式","authors":"N. Jain, S. O'brien","doi":"10.1097/PPO.0000000000000417","DOIUrl":null,"url":null,"abstract":"Abstract Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"The Shifting Paradigm in Chronic Lymphocytic Leukemia\",\"authors\":\"N. Jain, S. O'brien\",\"doi\":\"10.1097/PPO.0000000000000417\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.\",\"PeriodicalId\":22430,\"journal\":{\"name\":\"The Cancer Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Cancer Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/PPO.0000000000000417\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Cancer Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PPO.0000000000000417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 6

摘要

化学免疫疗法(CIT)是近20年来慢性淋巴细胞白血病患者的标准治疗方法。近年来，随着靶向治疗的引入，CIT的作用明显下降。在一线环境中，CIT的作用仅限于免疫球蛋白重链可变区突变且没有del(17p)/TP53突变的年轻健康患者。CIT在复发性慢性淋巴细胞白血病中的作用有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Shifting Paradigm in Chronic Lymphocytic Leukemia

Abstract Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Cancer Journal

自引率

0.00%

发文量